NVCR NovoCure Limited Stock Quote

NVCR [NASD]

Healthcare | Medical Instruments & Supplies | USA

Index	-	P/E	-	EPS (ttm)	-0.57	Insider Own	1.10%	Shs Outstand	104.19M	Perf Week	22.58%
Market Cap	7.04B	Forward P/E	-	EPS next Y	-0.63	Insider Trans	-4.41%	Shs Float	90.49M	Perf Month	-10.18%
Income	-58.90M	PEG	-	EPS next Q	-0.15	Inst Own	78.80%	Short Float	8.98%	Perf Quarter	-9.40%
Sales	537.90M	P/S	13.08	EPS this Y	-819.30%	Inst Trans	3.15%	Short Ratio	11.87	Perf Half Y	-12.91%
Book/sh	4.18	P/B	17.23	EPS next Y	-13.00%	ROA	-5.20%	Target Price	102.75	Perf Year	-67.67%
Cash/sh	9.55	P/C	7.55	EPS next 5Y	-	ROE	-14.20%	52W Range	56.39 - 226.14	Perf YTD	-4.06%
Dividend	-	P/FCF	195.42	EPS past 5Y	18.20%	ROI	-5.20%	52W High	-68.15%	Beta	0.94
Dividend %	-	Quick Ratio	8.20	Sales past 5Y	45.20%	Gross Margin	78.40%	52W Low	27.74%	ATR	4.76
Employees	1167	Current Ratio	8.50	Sales Q/Q	2.10%	Oper. Margin	-8.40%	RSI (14)	51.82	Volatility	8.63% 6.37%
Optionable	Yes	Debt/Eq	1.29	EPS Q/Q	-10.90%	Profit Margin	-10.90%	Rel Volume	0.65	Prev Close	74.69
Shortable	Yes	LT Debt/Eq	1.29	Earnings	Apr 28 BMO	Payout	-	Avg Volume	684.60K	Price	72.03
Recom	2.60	SMA20	1.04%	SMA50	-2.21%	SMA200	-16.93%	Volume	445,093	Change	-3.56%

May-16-22

Initiated

H.C. Wainwright

Buy

$115

Feb-08-22

Initiated

Loop Capital

Buy

$200

Feb-02-22

Upgrade

Oppenheimer

Perform → Outperform

$98

Jan-20-22

Upgrade

Truist

Hold → Buy

$125

Jan-03-22

Upgrade

Evercore ISI

Underperform → In-line

$82

Jul-01-21

Downgrade

Mizuho

Buy → Neutral

Apr-14-21

Downgrade

Wedbush

Neutral → Underperform

$159 → $154

Jan-25-21

Reiterated

Piper Sandler

Overweight

$140 → $225

Sep-23-20

Initiated

Northland Capital

Outperform

$200

Sep-18-20

Downgrade

Wells Fargo

Overweight → Equal Weight

$116

Sep-17-20

Downgrade

Truist

Buy → Hold

$108

Jun-01-20

Resumed

Oppenheimer

Perform

May-01-20

Downgrade

Oppenheimer

Outperform → Perform

Apr-09-20

Downgrade

Evercore ISI

In-line → Underperform

$58

Mar-05-20

Upgrade

Wells Fargo

Equal Weight → Overweight

$85 → $90

Jan-02-20

Downgrade

Evercore ISI

Outperform → In-line

$84 → $90

Jul-29-19

Upgrade

SunTrust

Hold → Buy

Jul-26-19

Downgrade

Wedbush

Outperform → Neutral

$57 → $80

Jul-26-19

Downgrade

JP Morgan

Overweight → Neutral

$61 → $79

Mar-20-19

Initiated

SunTrust

Hold

Jun-23-22 07:46AM	Strength Seen in NovoCure (NVCR): Can Its 8% Jump Turn into More Strength? Zacks +11.30%
Jun-21-22 08:00AM	Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer Business Wire
Jun-16-22 04:25PM	Why Novocure Stock Is Plunging This Week Motley Fool -6.97%
Jun-13-22 09:03AM	3 Stocks That Could Help You Retire a Millionaire Motley Fool -9.91%
Jun-11-22 06:05AM	3 Stocks Down 50% or More That You Can Buy Right Now Motley Fool
Jun-03-22 08:00AM	Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer GlobeNewswire -6.13%
08:00AM	Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer Business Wire
May-28-22 06:55AM	3 Stocks That Could Easily Turn $10,000 Into $50,000 by 2030 Motley Fool
May-26-22 08:00AM	Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma Business Wire +6.09%
May-23-22 12:26PM	Are Investors Undervaluing NovoCure Limited (NASDAQ:NVCR) By 47%? Simply Wall St.
May-12-22 01:00PM	AeroClean Announces Appointment of Timothy J. Scannell to Board of Directors GlobeNewswire
May-02-22 06:02AM	3 Beaten-Down Stocks That Could Deliver 5X Gains By 2030 Motley Fool +6.25%
Apr-28-22 01:30PM	Novocure (NVCR) Q1 2022 Earnings Call Transcript Motley Fool
08:35AM	NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:00AM	Novocure Reports First Quarter 2022 Financial Results Business Wire
Apr-22-22 04:00PM	The FDA Will Soon Give These 3 Healthcare Companies the Green Light Motley Fool -5.31%
Apr-19-22 04:45PM	Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu Business Wire +5.05%
Apr-14-22 05:52AM	3 Stocks That Could Realistically Turn $300,000 Into $1 Million by 2030 Motley Fool
Apr-11-22 11:30AM	2 Under-the-Radar Biotech Stocks to Buy in 2022 Motley Fool
Apr-08-22 12:08PM	NovoCure (NASDAQ:NVCR) delivers shareholders enviable 52% CAGR over 5 years, surging 3.8% in the last week alone Simply Wall St.
07:00AM	Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields Business Wire
06:00AM	This Up-and-Coming Healthcare Stock Could Skyrocket Motley Fool
05:55AM	3 Growth Stocks to Buy With $1,000 Right Now Motley Fool
Apr-03-22 06:10AM	3 Biotech Stocks to Buy in April Motley Fool
Apr-01-22 07:30AM	Novocure to Report First Quarter 2022 Financial Results Business Wire +5.81%
Mar-25-22 07:50AM	Novocure's TTFields Show Improved Progression-Free, Overall Survival Over Matched-Control Benzinga
07:00AM	This Incredibly Promising Stock Will Trade Like a Volatile Biotech Motley Fool
Mar-24-22 04:00PM	Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial Business Wire
Mar-23-22 08:00AM	Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer Business Wire
Mar-13-22 06:04AM	5 Growth Stocks That Can Turn $250,000 Into $1 Million by 2030 Motley Fool
Mar-06-22 07:04AM	3 Biotech Stocks That Can Make You Richer in March (and Beyond) Motley Fool
Feb-28-22 07:00AM	Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation Business Wire
Feb-24-22 04:24PM	Novocures General Counsel Resigns After 10 Years of Service Business Wire +6.76%
02:00PM	Novocure (NVCR) Q4 2021 Earnings Call Transcript Motley Fool
08:35AM	NovoCure (NVCR) Reports Q4 Loss, Lags Revenue Estimates Zacks
07:05AM	New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response Business Wire
07:00AM	Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update Business Wire
Feb-20-22 06:04AM	3 Stocks With Lower Market Caps Than Shiba Inu to Buy Right Now Motley Fool
Feb-18-22 04:00PM	Scared of the Bear? Buy These 3 Healthcare Stocks Motley Fool
Feb-17-22 03:03PM	Analysts Estimate NovoCure (NVCR) to Report a Decline in Earnings: What to Look Out for Zacks -5.16%
Feb-16-22 08:15AM	Charles River Laboratories (CRL) Tops Q4 Earnings and Revenue Estimates Zacks
Feb-08-22 09:38AM	Private Harbour Investment Management & Counsel, L Buys Chevron Corp, Invesco Optimum Yield ... GuruFocus.com
Feb-04-22 09:00AM	3 Amazing Stocks That Are 60% Off Their Highs Motley Fool
08:08AM	Is It Too Late To Consider Buying NovoCure Limited (NASDAQ:NVCR)? Simply Wall St.
05:52AM	3 Growth Stocks to Buy That Have Crashed More Than 60% Motley Fool
Feb-03-22 05:45PM	Avantor, Inc. (AVTR) Q4 Earnings and Revenues Top Estimates Zacks -6.01%
09:38AM	Schnieders Capital Management Llc Buys PagerDuty Inc, 3M Co, iShares TIPS Bond ETF, Sells ... GuruFocus.com
Feb-02-22 01:38PM	C WorldWide Group Holding A Buys Adobe Inc, Align Technology Inc, NovoCure, Sells Visa Inc, ... GuruFocus.com
01:38PM	Pictet & Cie (Europe) SA Buys Thermo Fisher Scientific Inc, Air Products & Chemicals ... GuruFocus.com
01:38PM	Banque Pictet & Cie Sa Buys Tesla Inc, Mastercard Inc, Thermo Fisher Scientific Inc, Sells ... GuruFocus.com
09:38AM	Everett Harris & Co Buys Bank of America Corp, Becton, Dickinson and Co, Comcast Corp, ... GuruFocus.com
Jan-30-22 06:10AM	3 Healthcare Stocks That Are Too Cheap to Ignore Motley Fool
Jan-29-22 07:55AM	Forget Novocure's Big Drop; Focus on the Long Term Motley Fool
Jan-27-22 01:38PM	Morgan Jess S & Co Inc Buys Wells Fargo, PowerShares QQQ Trust Ser 1, NVIDIA Corp, Sells ... GuruFocus.com
Jan-26-22 05:38PM	Patten & Patten Inc Buys JPMorgan Equity Premium Income ETF, Delta Air Lines Inc, Lincoln ... GuruFocus.com
Jan-20-22 11:43AM	Why Novocure Stock Is Jumping Today Motley Fool +9.22%
Jan-12-22 09:38AM	West Oak Capital, LLC Buys Citigroup Inc, Merck Inc, Vanguard Short-Term Corporate Bond ETF, ... GuruFocus.com +6.25%
Jan-10-22 04:24PM	Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer Investor's Business Daily
07:00AM	Novocure Announces Preliminary Full Year and Fourth Quarter 2021 Net Revenues and Provides Company Update Business Wire
Jan-08-22 11:00AM	3 Top Healthcare Stocks to Buy for January Motley Fool
Jan-06-22 07:56AM	7 Pharmaceutical Stocks That Could Make You Rich InvestorPlace
Jan-04-22 08:00AM	Novocure to Participate in the 40th Annual J.P. Morgan Healthcare Conference Business Wire -5.54%
Dec-19-21 06:38AM	Timothy Plan Israel Common Values Fund Buys Kornit Digital, Fattal Holdings (1998), Energean ... GuruFocus.com
Dec-17-21 08:38PM	Baillie Gifford Funds Buys Sprout Social Inc, Upwork Inc, TransMedics Group Inc, Sells Cloudera ... GuruFocus.com
Dec-15-21 03:38PM	NovoCure Limited (NVCR) Fell Out Of Favor With Hedge Funds Insider Monkey
Dec-07-21 04:11PM	Novocure Signs Agreement to Acquire and Construct Building in Downtown Portsmouth, New Hampshire Business Wire +7.97%
Dec-06-21 07:38PM	Reynolds Funds Inc Buys Costco Wholesale Corp, The Home Depot Inc, Visa Inc, Sells Alibaba ... GuruFocus.com
08:11AM	What Is The Ownership Structure Like For NovoCure Limited (NASDAQ:NVCR)? Simply Wall St.
08:00AM	Novocure Announces 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program Business Wire
Dec-03-21 08:10AM	Is It Time to Buy the 3 Worst-Performing Growth Stocks of 2021? Motley Fool -10.19%
Dec-02-21 06:28AM	Is Now the Right Time to Buy NovoCure? Motley Fool
Nov-23-21 07:30AM	Novocure to Participate in Two Upcoming Investor Conferences Business Wire
Nov-15-21 03:19PM	Novocure Posts Data For Tumor Treating Fields In Brain Tumor Trial Benzinga
07:31AM	2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma Business Wire
07:30AM	Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2021 Annual Meeting Business Wire
Nov-13-21 06:04AM	What's the Outlook for Novocure? Motley Fool
Oct-29-21 08:20AM	3 Healthcare Stocks That Could Be Turkeys in November Motley Fool
Oct-28-21 05:01PM	NovoCure (NVCR) Q3 2021 Earnings Call Transcript Motley Fool -8.16%
04:29PM	Why NovoCure Stock Is Sinking This Week Motley Fool
08:55AM	NovoCure (NVCR) Reports Q3 Loss, Misses Revenue Estimates Zacks
06:30AM	Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update Business Wire
06:30AM	Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer Business Wire
Oct-25-21 05:23PM	Here is What Hedge Funds Think About NovoCure Limited (NVCR) Insider Monkey
Oct-21-21 03:03PM	Analysts Estimate NovoCure (NVCR) to Report a Decline in Earnings: What to Look Out for Zacks
07:30AM	Novocure Announces 15 Presentations at the American Society for Radiation Oncology 2021 Annual Meeting Business Wire
Oct-17-21 06:04AM	3 Stocks to Consider if the October Stock Market Sell-Off Worsens Motley Fool
Oct-14-21 11:30AM	This Unstoppable Cancer-Treatment Company's Stock Is on Sale Now Motley Fool
Oct-12-21 10:00AM	Accuray (ARAY), C-RAD Ink Deal to Enhance Breast Cancer Treatment Zacks
08:50AM	This Company's Device is Becoming Essential to Cancer Treatment -- Why Is the Stock Slumping? Motley Fool
Oct-11-21 05:03AM	Have Patience as NovoCure Looks for a New Bottom Pattern TheStreet.com
Oct-10-21 07:31AM	3 Stocks Wall Street Thinks Will Soar 44% to 122% That You'll Want to Check Out Motley Fool
Oct-06-21 11:16AM	Returns Are Gaining Momentum At NovoCure (NASDAQ:NVCR) Simply Wall St.
Oct-04-21 07:30AM	Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China GlobeNewswire -5.75%
07:30AM	Novocure to Report Third Quarter 2021 Financial Results Business Wire
07:30AM	Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China Business Wire
Sep-14-21 08:34AM	Novocure To Test Its Tumor Treating Fields With Roche's Tecentriq In Pancreatic Cancer Benzinga
07:00AM	Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer Business Wire
Sep-09-21 11:12AM	This Promising Healthcare Stock Is Down 50% From Its Highs; Should You Buy the Dip? Motley Fool
08:14AM	FDA Grants Breakthrough Device Designation to the NovoTTF-200T System for Advanced Liver Cancer Business Wire
Sep-02-21 06:00AM	Novocure to Participate in the 2021 Wells Fargo Virtual Healthcare Conference Business Wire

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma. The company markets its products in the European Union, the United Kingdom, Japan, and internationally. It has a clinical study collaboration agreement with MSD to study TTFields together with KEYNOTE, an anti-PD-1 therapy; and a strategic collaboration with Zai Lab (Shanghai) Co., Ltd. to commercialize its products in Greater China and establishes a development partnership intended to accelerate the development of TTFields in multiple solid tumor cancer indications. NovoCure Limited was incorporated in 2000 and is based in Saint Helier, Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HILLEMAN JERYL L	Director	Jun 10	Sale	69.61	407	28,331	2,537	Jun 16 04:22 PM
Benaim Ely	Chief Medical Officer	May 11	Sale	61.25	2,135	130,769	34,846	May 12 04:30 PM
Benaim Ely	Chief Medical Officer	May 10	Sale	65.16	2,070	134,877	36,981	May 12 04:30 PM
Shah Pritesh	Chief Commercial Officer	Mar 09	Sale	71.19	3,669	261,196	83,187	Mar 11 04:54 PM
Leonard Frank X	Chief Development Officer	Mar 08	Sale	70.10	744	52,154	102,295	Mar 09 04:55 PM
Burke William Patrick	Chief Human Resources Officer	Mar 08	Sale	70.10	1,037	72,694	55,991	Mar 09 04:53 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Mar 08	Sale	70.10	2,923	204,902	165,102	Mar 09 04:52 PM
Cordova Ashley	Chief Financial Officer	Mar 08	Sale	70.10	759	53,206	60,848	Mar 09 04:51 PM
Longsworth Todd Christopher	General Counsel	Mar 08	Sale	70.10	2,339	163,964	62,462	Mar 09 04:50 PM
DOYLE WILLIAM F	Executive Chairman	Mar 08	Sale	70.10	2,385	167,188	552,013	Mar 09 04:48 PM
Shah Pritesh	Chief Commercial Officer	Mar 08	Sale	70.10	2,481	173,918	81,908	Mar 09 04:56 PM
Shah Pritesh	Chief Commercial Officer	Mar 07	Sale	69.55	5,294	368,198	84,389	Mar 09 04:56 PM
Leonard Frank X	Chief Development Officer	Mar 04	Sale	70.41	555	39,076	103,039	Mar 07 06:14 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Mar 04	Sale	70.41	2,569	180,876	168,025	Mar 07 06:16 PM
Burke William Patrick	Chief Human Resources Officer	Mar 04	Sale	70.41	1,026	72,238	57,028	Mar 07 06:17 PM
Benaim Ely	Chief Medical Officer	Mar 04	Sale	70.41	1,510	106,315	43,257	Mar 07 06:18 PM
Shah Pritesh	Chief Commercial Officer	Mar 04	Sale	72.11	4,546	327,790	89,683	Mar 07 06:23 PM
Cordova Ashley	Chief Financial Officer	Mar 04	Sale	70.41	556	39,146	61,607	Mar 07 06:26 PM
Longsworth Todd Christopher	General Counsel	Mar 04	Sale	70.41	1,973	138,913	64,801	Mar 07 06:28 PM
Cordova Ashley	Chief Financial Officer	Mar 03	Option Exercise	14.61	5,040	73,656	65,888	Mar 11 04:55 PM
Longsworth Todd Christopher	General Counsel	Mar 03	Sale	74.50	1,094	81,501	66,774	Mar 07 06:28 PM
Cordova Ashley	Chief Financial Officer	Mar 03	Sale	74.50	1,149	85,598	62,163	Mar 07 06:26 PM
Shah Pritesh	Chief Commercial Officer	Mar 03	Sale	74.50	997	74,275	94,229	Mar 07 06:23 PM
Benaim Ely	Chief Medical Officer	Mar 03	Sale	74.50	803	59,822	44,767	Mar 07 06:18 PM
Burke William Patrick	Chief Human Resources Officer	Mar 03	Sale	74.50	341	25,404	58,054	Mar 07 06:17 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Mar 03	Sale	74.50	1,301	96,922	170,594	Mar 07 06:16 PM
Leonard Frank X	Chief Development Officer	Mar 03	Sale	74.50	930	69,283	103,594	Mar 07 06:14 PM
Burke William Patrick	Chief Human Resources Officer	Jan 03	Option Exercise	10.49	28,604	299,996	51,269	Jan 05 04:52 PM
Burke William Patrick	Chief Human Resources Officer	Jan 03	Sale	76.00	3,951	300,263	41,036	Jan 05 04:52 PM
Danziger Asaf	Chief Executive Officer	Nov 26	Buy	102.44	4,974	509,539	13,276	Nov 29 04:48 PM
Cordova Ashley	Chief Financial Officer	Nov 02	Sale	107.28	209	22,421	41,758	Nov 03 04:11 PM
Shah Pritesh	Chief Commercial Officer	Sep 03	Sale	138.68	501	69,477	73,512	Sep 07 04:32 PM
Leonard Frank X	Chief Development Officer	Sep 02	Sale	138.23	540	74,645	87,153	Sep 07 04:39 PM
Cordova Ashley	Chief Financial Officer	Sep 02	Sale	138.23	828	114,456	41,967	Sep 07 04:37 PM
GROENHUYSEN WILHELMUS CM	Chief Operating Officer	Sep 02	Sale	138.23	181	25,020	149,899	Sep 07 04:35 PM
Shah Pritesh	Chief Commercial Officer	Sep 02	Sale	138.23	156	21,564	74,013	Sep 07 04:32 PM
Cordova Ashley	Chief Financial Officer	Aug 12	Option Exercise	28.82	36,624	1,055,329	54,019	Aug 16 04:40 PM
Cordova Ashley	Chief Financial Officer	Aug 12	Sale	140.94	26,624	3,752,286	45,993	Aug 16 04:40 PM
LEUNG GABRIEL	Director	Aug 05	Option Exercise	31.45	1,000	31,450	73,859	Aug 06 04:39 PM
LEUNG GABRIEL	Director	Aug 05	Sale	152.50	1,000	152,500	72,859	Aug 06 04:39 PM
Madden Martin J.	Director	Aug 05	Sale	153.13	34	5,206	384	Aug 06 04:44 PM
Shah Pritesh	Chief Commercial Officer	Aug 04	Sale	148.71	2,063	306,789	74,169	Aug 06 04:41 PM
Leonard Frank X	Chief Development Officer	Aug 03	Sale	149.43	328	49,013	89,158	Aug 04 05:20 PM
Benaim Ely	Chief Medical Officer	Aug 03	Sale	150.11	464	69,651	28,144	Aug 04 04:59 PM
Shah Pritesh	Chief Commercial Officer	Aug 03	Sale	149.43	1,654	247,157	76,232	Aug 04 05:09 PM
DOYLE WILLIAM F	Executive Chairman	Aug 02	Sale	149.38	995	148,631	554,398	Aug 04 05:01 PM
Benaim Ely	Chief Medical Officer	Aug 02	Sale	149.38	536	80,067	28,608	Aug 03 05:29 PM
Leonard Frank X	Chief Development Officer	Aug 02	Sale	149.38	713	106,507	89,486	Aug 04 05:20 PM
Shah Pritesh	Chief Commercial Officer	Jul 31	Option Exercise	154.01	3,717	572,455	85,625	Mar 11 04:54 PM
Benaim Ely	Chief Medical Officer	Jul 30	Option Exercise	83.30	651	54,228	29,795	Aug 03 05:29 PM
Benaim Ely	Chief Medical Officer	Jul 30	Sale	158.96	651	103,483	29,144	Aug 03 05:29 PM
LEUNG GABRIEL	Director	Jul 06	Option Exercise	31.45	1,000	31,450	73,859	Jul 08 05:23 PM
LEUNG GABRIEL	Director	Jul 06	Sale	183.54	1,000	183,540	72,859	Jul 08 05:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience